Skip to content
Advertisement

FILE - In this Wednesday, Sept. 2, 2020 file photo, blood samples from volunteers participating in the National Institutes of Health-funded Moderna COVID-19 vaccine third phase clinical trail wait to be processed in a lab at the University of Miami Miller School of Medicine in Miami. Creating vaccines and properly testing them less than a year after the world discovered a never-before-seen disease is incredible. But the two U.S. frontrunners are made in a way that promises speedier development may become the norm -- especially if they prove to work long-term as well as they have in early testing. (AP Photo/Taimy Alvarez)

FILE - In this Wednesday, Sept. 2, 2020 file photo, blood samples from volunteers participating in the National Institutes of Health-funded Moderna COVID-19 vaccine third phase clinical trail wait to be processed in a lab at the University of Miami Miller School of Medicine in Miami. Creating vaccines and properly testing them less than a year after the world discovered a never-before-seen disease is incredible. But the two U.S. frontrunners are made in a way that promises speedier development may become the norm -- especially if they prove to work long-term as well as they have in early testing. (AP Photo/Taimy Alvarez)

Featured Photo Galleries